A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 30 Mar 2016 Status changed from suspended to active, no longer recruiting as per ClinicalTrials.gov record.